Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a Healthcare company (Biotechnology) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
Intellia Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.78, Intellia Therapeutics, Inc. trades at 26.6x sales and 2.3x book value. Over the last twelve months it generated about $52M of revenue and a net loss of $460M. It runs a gross margin of 84.5%, an operating margin of -821.2% and a net margin of -805.7%. It shows return on equity of -64.7%, return on invested capital of -51.5% and a free cash flow yield of -26.1%. On the balance sheet: a debt-to-equity ratio of 0.38 and a current ratio of 6.31. Over the past 52 weeks the share price ranged from $7.95 to $18.48, with a beta of 1.82.
Intellia Therapeutics, Inc. does not currently pay a dividend.
39 Wall Street analyst ratings cover the stock: 29 Buy, 7 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Intellia Therapeutics, Inc. (NTLA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.55% / 30% · (Cash+Inv) / Mkt Cap (36m) 38.7% / 30% · Interest income / Revenue 81.5% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 4.55% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 29.3% / 33% · Receivables / Mkt Cap (36m) 0.46% / 49% · Interest income / Revenue 81.5% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 4.55% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 29.3% / 33.33% · Receivables / Mkt Cap (24m) 0.46% / 33.33% · Interest income / Revenue 81.5% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 6.01% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 51.7% / 33.33% · Receivables / Avg Assets (4Q) 0.99% / 33.33% · Interest income / Revenue 81.5% / 5% | Fail |
| FTSE | Debt / Total Assets 8.17% / 33.33% · (Cash+ST Inv) / Total Assets 52.5% / 33.33% · (Cash+Recv) / Total Assets 53.4% / 33.33% · Interest income / Revenue 81.5% / 5% | Fail |
No. As of September 2026, Intellia Therapeutics, Inc. (NTLA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Intellia Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 81.5% of each dividend: Intellia Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.